Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Regenxbio (RGNX) over the last 11 years, with Q3 2025 value amounting to $1.8 million.

  • Regenxbio's Amortizatization of Intangibles rose 3852.58% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 6417.86%. This contributed to the annual value of $4.1 million for FY2024, which is 70320.23% up from last year.
  • Latest data reveals that Regenxbio reported Amortizatization of Intangibles of $1.8 million as of Q3 2025, which was up 3852.58% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Amortizatization of Intangibles registered a high of $1.8 million during Q3 2025, and its lowest value of -$1.6 million during Q2 2021.
  • Moreover, its 5-year median value for Amortizatization of Intangibles was -$380000.0 (2023), whereas its average is -$149842.1.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first tumbled by 320256.41% in 2021, then skyrocketed by 88947.37% in 2024.
  • Quarter analysis of 5 years shows Regenxbio's Amortizatization of Intangibles stood at -$1.5 million in 2021, then soared by 38.36% to -$903000.0 in 2022, then skyrocketed by 126.8% to $242000.0 in 2023, then surged by 361.57% to $1.1 million in 2024, then skyrocketed by 63.21% to $1.8 million in 2025.
  • Its Amortizatization of Intangibles stands at $1.8 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.1 million for Q1 2025.